Warfarin treatment and risk of stroke among primary care patients with atrial fibrillation

被引:7
|
作者
Wandell, Per [1 ,2 ]
Carlsson, Axel C. [1 ,3 ]
Holzmann, Martin J. [4 ,5 ]
Arnlov, Johan [3 ,6 ]
Johansson, Sven-Erik [7 ]
Sundquist, Jan [7 ]
Sundquist, Kristina [7 ]
机构
[1] Karolinska Inst, Div Family Med, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden
[2] Stockholm Cty Council, Acad Primary Healthcare Ctr, Huddinge, Sweden
[3] Uppsala Univ, Dept Med Sci, Cardiovasc Epidemiol, Uppsala, Sweden
[4] Karolinska Univ Hosp, Dept Emergency Med, Stockholm, Sweden
[5] Karolinska Inst, Dept Internal Med, Stockholm, Sweden
[6] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden
[7] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
关键词
Atrial fibrillation; ischaemic stroke; gender; follow-up; co-morbidity; anticoagulant; STRATIFICATION SCHEMES; FOLLOW-UP; STOCKHOLM; ASPIRIN; SWEDEN; COHORT; ANTICOAGULATION; HYPERTENSION; EXPERIENCE; BENEFIT;
D O I
10.1080/14017431.2016.1215519
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Our aim was to study the risk of a first ischaemic stroke (IS) in patients with atrial fibrillation (AF) treated in primary healthcare. Design. The study population included all adults (n=11,517), 45 years and older diagnosed with AF, from 75 primary care centres in Sweden between 2001 and 2007. IS was defined as a hospital care event of stroke between 2001 and 2010. Association between incident stroke and warfarin treatment was explored using Cox regression analysis, with hazard ratios (HRs), and 95% confidence intervals (95%CIs). Adjustment was made for age, socioeconomic factors and co-morbidity. Results. Persistent treatment with warfarin was present among 33.7% of women and 40.0% among men. Persistent warfarin treatment, compared to no persistent treatment, was associated with a stroke preventing effect with fully adjusted HRs of 0.25 (95%CI 0.18-0.36) in women, and 0.25 (95%CI 0.19-0.32) in men. A CHA(2)DS(2)-VASc score of at least two among women, and three among men, was associated with a stroke risk exceeding 18% during a mean follow-up of 5.4 years. Risk of haemorrhagic stroke was not increased. Conclusions. Warfarin is effective in preventing stroke in AF patients in primary healthcare.
引用
收藏
页码:311 / 316
页数:6
相关论文
共 50 条
  • [31] Warfarin persistence among atrial fibrillation patients - why is treatment ended?
    Bjorck, Fredrik
    Ek, Agnes
    Johansson, Lars
    Sjalander, Anders
    CARDIOVASCULAR THERAPEUTICS, 2016, 34 (06) : 468 - 474
  • [33] Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
    Hankey, GJ
    Klijn, CJM
    Eikelboom, JW
    STROKE, 2004, 35 (02) : 389 - 391
  • [34] Warfarin and Stroke Outcomes in Hemodialysis Patients with Atrial Fibrillation
    Genovesi, Simonetta
    Santoro, Antonio
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10): : 2090 - 2092
  • [35] Risk of stroke overall and by stroke severity among newly diagnosed non-valvular atrial fibrillation patients initiating treatment with rivaroxaban versus warfarin
    Alberts, M.
    Lin, J. H.
    Chen, Y. -W.
    Ding, Z.
    Bisht, D.
    Kogan, E.
    Twyman, K.
    Milentijevic, D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 821 - 821
  • [36] The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden
    Ingela Björholt
    Stina Andersson
    Gunnar H Nilsson
    Ingvar Krakau
    BMC Family Practice, 8
  • [37] The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden
    Bjoerholt, Ingela
    Andersson, Stina
    Nilsson, Gunnar H.
    Krakau, Ingvar
    BMC FAMILY PRACTICE, 2007, 8 (1)
  • [38] Warfarin exposure and the risk of nonhemorrhagic stroke and bleeding events among Medicaid patients with atrial fibrillation: A retrospective analysis
    Boulanger, L
    Hauch, O
    Friedman, M
    Dixon, D
    Wygant, G
    Menzin, J
    CIRCULATION, 2004, 109 (20) : E269 - E269
  • [40] Risk-treatment paradox regarding the use of Warfarin for stroke prevention in atrial fibrillation
    Lam, Y. -Y.
    Poon, J. Y.
    Cheung, C. K.
    Chui, Y. K.
    Li, H. M.
    Yee, S. H.
    Chan, C. P.
    Yu, C. M.
    EUROPEAN HEART JOURNAL, 2011, 32 : 561 - 562